FeesSafety
Pluang+

Health In Tech to report Q3 2026 earnings on Nov 12 with a live webcast and call.

Company Fundamentals
29 Oct 2026, 13:30 WIB
PRNewsWire
View Source
Neutral
Health In Tech to report Q3 2026 earnings on Nov 12 with a live webcast and call.

Health In Tech, an AI-driven InsurTech platform, announced it will release its financial results for the third quarter ending September 30, 2026, on November 12 after market close. The company will host a conference call and live webcast to discuss these results, recent developments, and future outlook. Health In Tech's platform simplifies health insurance processes through automation and serves brokers and insurers with AI-enabled tools. Investors can access the webcast live or via replay on the company's website.

Health In Tech's upcoming Q3 2026 financial results provide context for readers following health-related tech developments. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 16:11 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 86 rose and 57 fell today. Notable movers include INO (Inovio Pharmaceuticals Inc) at USD 0.96 with a 1-day change of +3.22%, SANA (Sana Biotechnology Inc) at USD 2.71 with +3.04%, and GILD (Gilead Sciences, Inc.) at USD 163.74 with +2.85%. The most notable figure is GILD's Pluang order activity showing 87% Buy interest and a typical hold time of 114 days.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App